For staging and detection of cholangiocarcinoma, which PET tracer is preferred: 18F‑FDG (fluorodeoxyglucose) or 68Ga‑FAPI (fibroblast activation protein inhibitor)?

68Ga-FAPI PET/CT is Superior to 18F-FDG PET/CT for Staging and Detection of Cholangiocarcinoma

For staging and detection of cholangiocarcinoma, 68Ga-FAPI PET/CT should be the preferred tracer over 18F-FDG PET/CT, based on consistently superior sensitivity for detecting primary tumors, lymph node metastases, and distant metastases.

Diagnostic Performance: FAPI Demonstrates Clear Superiority

The most recent and highest-quality evidence comes from a 2025 systematic review and meta-analysis specifically examining biliary tract cancers 1. This study demonstrated that 68Ga-FAPI PET/CT achieved significantly better detection rates than 18F-FDG PET/CT with a pooled odds ratio of 4.87 (95% CI: 1.75-13.56) favoring FAPI. For intrahepatic cholangiocarcinoma specifically, the odds ratio was 2.98, still favoring FAPI.

Primary Tumor Detection

• FAPI sensitivity: 94.3% (95% CI: 90.6-96.8%)
• FDG sensitivity: 56.1% (95% CI: 49.7-62.5%)

A prospective head-to-head comparison 2 showed FAPI detected 100% of primary biliary tract cancers (16/16) versus only 81% for FDG (13/16). This difference is clinically critical—missing nearly 1 in 5 primary tumors with FDG could fundamentally alter treatment planning.

Lymph Node Metastases

FAPI demonstrates substantially higher sensitivity for nodal disease:

• FAPI detected 98% of lymph node metastases (41/42) 2
• FDG detected only 83% (35/42)
• Pooled odds ratio: 2.81 (95% CI: 1.07-7.35) favoring FAPI 1

Distant Metastases

FAPI achieved 100% detection of distant metastases (99/99) compared to 79% for FDG (78/99) 2. The pooled odds ratio for distant metastasis detection was 3.45 (95% CI: 1.12-10.63) 1.

Tumor Uptake Characteristics

FAPI demonstrates significantly higher tumor-to-background contrast:

• SUVmax difference: 6.47 higher for FAPI (95% CI: 1.81-11.13) 1
• Tumor-to-background ratio (TBR) difference: 9.45 higher for FAPI (95% CI: 3.88-15.03) 1

In cholangiocarcinoma specifically, average SUVmax was 18.2 ± 6.4 for FAPI versus 9.1 ± 5.0 for FDG (p=0.007) 3. This superior contrast enables detection of smaller lesions and better delineation of tumor extent.

Clinical Impact on Staging and Management

The prospective study by Shi et al. 2 demonstrated that FAPI PET/CT changed clinical management in 56% of patients (10/18) by:

• Detecting previously unknown metastases
• Upstaging disease in 28% of patients (5/18)
• Identifying additional sites requiring treatment consideration

This is particularly important because cholangiocarcinoma treatment decisions—especially regarding surgical resectability—depend critically on accurate staging.

Critical Advantage: Distinguishing Tumor from Inflammation

A major pitfall with FDG in cholangiocarcinoma is false-positive uptake in inflammatory processes secondary to biliary obstruction. FAPI addresses this limitation:

• FAPI detected 88% of inflammatory processes (7/8) versus only 13% for FDG (1/8) 2
• Crucially, FAPI showed lower uptake in inflammation than tumor (SUVmax 4.9 ± 2.6 vs. 10.0 ± 4.6, p=0.003) 2

This allows differentiation between tumor and post-obstructive inflammation—a distinction that FDG cannot reliably make.

Guideline Context and Current Limitations

Current guidelines 4, 5, 6, 7 do not yet incorporate FAPI imaging, as they predate this technology. The 2025 EASL guidelines 6 recommend FDG-PET for identifying lymph node metastases not apparent on CT/MRI in extrahepatic cholangiocarcinoma, while the 2023 EASL guidelines 7 recommend FDG-PET for intrahepatic cholangiocarcinoma staging (both with moderate evidence levels).

However, these recommendations were based on FDG being the only available PET tracer. The newer FAPI data supersedes these recommendations given its demonstrated superiority across all metrics relevant to patient outcomes (accurate staging affects surgical candidacy, treatment selection, and prognosis).

Important Caveat: Availability and Validation

FAPI PET/CT is not yet widely available and remains investigational in many centers. Where FAPI is unavailable, FDG PET/CT remains useful for:

• Detecting distant metastases (sensitivity 97%, specificity 75%) 8
• Identifying unsuspected lymph node involvement

However, clinicians must recognize FDG's limitations in cholangiocarcinoma, particularly its poor sensitivity for primary tumors and tendency for false-positives in inflamed/obstructed bile ducts.

Practical Algorithm for Cholangiocarcinoma Staging

If FAPI PET/CT is available:

1. Perform 68Ga-FAPI PET/CT as primary metabolic imaging modality
2. Combine with contrast-enhanced MRI/MRCP for anatomic detail 6, 7
3. Use for detecting primary tumor, nodal disease, and distant metastases
4. Particularly valuable when FDG shows equivocal findings or in presence of biliary obstruction/inflammation

If only FDG PET/CT is available:

1. Use FDG PET/CT primarily for detecting distant metastases and lymph node involvement
2. Interpret with caution in setting of biliary obstruction or inflammation
3. Do not rely solely on FDG for primary tumor detection (sensitivity only 56-81%)
4. Combine with high-quality MRI/MRCP and consider EUS-guided biopsy for tissue confirmation 6, 7

The evidence strongly supports transitioning to FAPI as the preferred PET tracer for cholangiocarcinoma once it becomes clinically available, given its superior performance across all clinically relevant endpoints and its ability to distinguish tumor from inflammation—a critical distinction that directly impacts treatment decisions and patient outcomes.